STAT+: A cautious culture cost Novo its obesity lead
And more biotech news updates, brought to you by The Readout.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. It’s hard to be the first company in a new disease area or drug class, and perhaps even harder to maintain a lead. We dig into that today.pharma
A cautious culture cost Novo its obesity lead
Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly. How did it get here? I spoke with former Novo employees to understand.
